Particle Therapy Market by Therapy Type, Component, Configuration, Cancer Type, End-User

Description

List of Tables

[193 Pages Report] The Particle Therapy Market size was estimated at USD 772.41 million in 2023 and expected to reach USD 831.50 million in 2024, at a CAGR 7.94% to reach USD 1,318.87 million by 2030.

The particle therapy forms a specific segment of the broader therapeutical technology. Primarily, it focuses on the global commercialization, distribution, and application of particle therapy technologies. Particle therapy utilizes charged and uncharged particles, such as protons and neutrons, within a controlled environment to target and eliminate cancer cells inside a patient's body. The effectiveness of this therapy in ensuring precision mainly drives market demand and growth. The increasing need for advanced therapies in cancer treatment and the rising adoption of particle therapy in clinical trials, fast, non-invasive, and painless procedures significantly contribute to driving this market growth. In contrast, limited insurance coverage for particle therapy and risk associated with particle therapy radiation exposure limits their utilization and penetrates the market growth. However, several vendors are developing more advanced and compact particle therapy systems and focusing on enhancing precision and minimizing potential side effects. Moreover, ongoing proton therapy research programs and technological advancements in charged-particle therapy are creating a myriad of opportunities for particle therapy expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 772.41 million
Estimated Year [2024]	USD 831.50 million
Forecast Year [2030]	USD 1,318.87 million
CAGR (%)	7.94%

Therapy Type: Consumer preference for proton therapy as it provides a reduced risk of damage to surrounding tissues

Heavy ion therapy employs densely ionized atoms such as carbon to initiate precise damage to cancer cells. The technique results in minimal damage to surrounding healthy tissue. This therapy is effective on radio-resistant tumors, providing an edge over traditional forms of radiotherapy. Proton therapy is increasingly preferred, especially in pediatrics, due to its damage-limiting property for surrounding tissues and organs, making a significant difference to patients with tumors near critical organs. Heavy ion therapy provides a promising solution for radio-resistant tumors, and proton therapy is often preferred for pediatric cancer patients because of its reduced risk of damage to surrounding tissues.

Component: Rising utilization of product components for treating solid tumors near vital organs due to their high accuracy

Particle therapy products primarily constitute equipment that delivers the target's particle beams. This includes machines such as cyclotrons, synchrocyclotrons, and synchrotrons. Cyclotrons are utilized to accelerate charged particles to high energies. Synchrocyclotrons are designed to overcome the frequency limitation of cyclotrons by altering the frequency of the accelerating electric field. This makes them ideal for particle therapy due to their ability to deliver high-energy beams effectively and accurately. Synchrotrons are particle accelerators but demonstrate more control over the energy of the accelerated particles, making them an excellent choice for particle therapy. They are often utilized in treating deep-seated and complex-shaped tumors. Particle therapy delivers high doses of radiation precisely to tumor cells and comes in different systems where each offers unique benefits depending upon the specific needs and situations of the healthcare establishment. The services segment includes installation, maintenance, training, and consulting services related to particle therapy systems. In comparison, the requirement for a product component is more imminent in countries with health institutes experiencing an influx of cancer patients and having the infrastructure to support a particle therapy unit. The service component's demand is more in countries where healthcare organizations are in the early stages of developing or planning to develop a particle therapy unit.

Configuration: Potential of a multi-room system for treating a larger number of patients concurrently

A multi-room system in particle therapy incorporates multiple treatment rooms, thus allowing more patients to receive treatment concurrently. These systems are immensely beneficial for large healthcare establishments, owing to the faster patient flow, the ability to treat complex cases, and the efficiency in maximizing the usage of particle accelerator facilities. Single-room systems are the ideal choice for smaller healthcare facilities that are starting to venture into the realm of particle therapy. They are generally easier to implement and manage due to the compact design and relatively simpler logistics. In comparison, multi-room systems are beneficial in treating a larger number of patients concurrently and cater to complex cases, and their implementation demands higher initial investment and operational complexity. On the contrary, single-room systems, with their compact design and manageable logistics, are easier to implement and operate, thus being a better fit for smaller healthcare facilities initiating their journey into particle therapy.

Cancer Type: Expanding usage of particle therapy for head & neck cancer owing to reduced risk on healthy tissue

Particle therapy, offering highly focused radiation, has brought about remarkable results in breast cancer management, especially for patients with recurring or aggressive forms of the disease. Particle therapy for head & neck cancer shows promising results due to the anatomical complexity of this region. The precise and high-dosage radiation from particle therapy minimizes the risk of excess radiation in healthy tissues around the tumor. Lung cancer, notorious for its resistance to traditional radiation therapy, has seen promising treatment outcomes through particle therapy. Particle therapy is considerably beneficial in treating pediatric cancers, reducing the long-term side effects usually associated with traditional radiation treatments. Prostate cancer treatment has been dramatically enhanced by particle therapy, given the highly effective and precise radiation techniques. In comparison, particle therapy has emerged as a new dawn in the field of head & neck cancer treatment, offering hope to patients battling various forms of the disease.

End-User: Significant role of particle therapy in hospitals & clinicals as they strive to provide high-quality care

Ambulatory surgery centers (ASCs) allow surgeons to deliver efficient, high-quality care at a lower cost. In particle therapy, these centers cater to instances where the cancer is well-defined and is treated in a few sessions. Hospitals and clinics offer more comprehensive care and cater to various cancer cases. They provide both proton and heavy ion therapies to treat a variety of cancers, including more complex issues. These institutions have large treatment facilities equipped with advanced particle therapy machines. Due to their nature of operation, ambulatory surgery centers embrace compact, streamlined designs best suited for less complex cases, striving for efficiency with limited space. Hospitals & clinics offer more robust treatment capabilities to manage various cases, from the simple to the complex.

Regional Insights

In America, the need for particle therapy has seen consistent growth. Technology innovation is frequent and heavily backed by both private and public organizations. This region holds the most significant market share due to extensive research activities and the rise of numerous startups funded by investors targeting therapy innovation. In the EMEA region, Europe exhibits formidable growth in particle therapy primarily due to the rising incidences of various cancer types and a growing elderly population at risk. Moreover, increased funding in healthcare from various governments and organizations, coupled with well-established healthcare facilities, allows for broader adoption of the technique. Middle Eastern and African countries also show promising growth, mainly due to rising healthcare expenditure and increased efforts to enhance healthcare infrastructure. In the APAC region, several economies are leading in adopting particle therapy for cancer treatment. Factors contributing to such progress include the increasing prevalence of cancer, rapid urbanization, and continually improving economic conditions. APAC offers a vast population base, which, combined with improving healthcare infrastructures and increasing government funding for cancer research and treatment, presents APAC as a fast-growing market for particle therapy.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Particle Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Particle Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Particle Therapy Market, highlighting leading vendors and their innovative profiles. These include Advanced Oncotherapy plc, B dot Medical Inc., Best Particle Therapy, Inc., BioSig Technologies Inc., Covenant Health, Danfysik A/S, Elekta AB, Hitachi, Ltd., IBA International, Koninklijke Philips N.V., Mevion Medical Systems, Mitsubishi Electric Corporation, New Mexico Cancer Center, Optivus Proton Therapy, Inc., P-Cure Ltd, ProTom International, Provision Healthcare, LLC, PTW Freiburg GmbH, SAH Global LLC, Shanghai APACTRON Particle Equipment Co., Ltd., Siemens Healthineers GmbH, Stantec Inc., Sumitomo Heavy Industries, Ltd., Toshiba Medical Systems Corporation, and Xstrahl Ltd..

Market Segmentation & Coverage

This research report categorizes the Particle Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapy Type
- Heavy Ion Therapy
- Proton Therapy

Component
- Product
  - Cyclotrons
  - Synchrocyclotrons
  - Synchrotrons

Service

Configuration
- Multi-room System
- Single-room System

Cancer Type
- Breast Cancer
- Head & Neck Cancer
- Lung Cancer
- Pediatric Cancer
- Prostate Cancer

End-User
- Ambulatory Surgery Centers
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Particle Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Particle Therapy Market?

3. What are the technology trends and regulatory frameworks in the Particle Therapy Market?

4. What is the market share of the leading vendors in the Particle Therapy Market?

5. Which modes and strategic moves are suitable for entering the Particle Therapy Market?

Product Code: MRR-335201F2E2B6

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Need for advanced therapies in cancer treatment
  - 5.1.1.2. Rise in adoption of particle therapy in clinical trials
  - 5.1.1.3. Growing number of particle therapy centers worldwide
- 5.1.2. Restraints
  - 5.1.2.1. High cost of particle therapy equipment and procedures, along with limited insurance coverage for particle therapy
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing proton therapy research programs
  - 5.1.3.2. Technological advances in charged-particle therapy and enabling personalized cancer treatment strategies
- 5.1.4. Challenges
  - 5.1.4.1. Risk associated with the particle therapy radiation exposure
5.2. Market Segmentation Analysis
- 5.2.1. Therapy Type: Consumer preference for proton therapy as it provides a reduced risk of damage to surrounding tissues
- 5.2.2. Component: Rising utilization of product components for treating solid tumors near vital organs due to their high accuracy
- 5.2.3. Configuration: Potential of a multi-room system for treating a larger number of patients concurrently
- 5.2.4. Cancer Type: Expanding usage of particle therapy for head & neck cancer owing to reduced risk on healthy tissue
- 5.2.5. End-User: Significant role of particle therapy in hospitals & clinicals as they strive to provide high-quality care
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Particle Therapy Market, by Therapy Type

6.1. Introduction
6.2. Heavy Ion Therapy
6.3. Proton Therapy

7. Particle Therapy Market, by Component

7.1. Introduction
7.2. Product
7.3. Service

8. Particle Therapy Market, by Configuration

8.1. Introduction
8.2. Multi-room System
8.3. Single-room System

9. Particle Therapy Market, by Cancer Type

9.1. Introduction
9.2. Breast Cancer
9.3. Head & Neck Cancer
9.4. Lung Cancer
9.5. Pediatric Cancer
9.6. Prostate Cancer

10. Particle Therapy Market, by End-User

10.1. Introduction
10.2. Ambulatory Surgery Centers
10.3. Hospitals & Clinics

11. Americas Particle Therapy Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Particle Therapy Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Particle Therapy Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. IBA and PARTICLE Initiate FLASH Proton Therapy Research Partnership
- 14.3.2. P-Cure Receives FDA Approval For Proton Therapy System For Treatment in Seated Position and Will Begin Treating Patients In Israel
- 14.3.3. Terapet raises CHF 2.3 million for its next-generation cancer treatment technology
14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio